Мобилизация гемопоэтических стволовых клеток из костного мозга в периферическую кровь у больных множественной миеломой

Автор: Кострома И.И., Сабитова Р.Р., Замотина Т.Б., Грицаев С.В., Бессмельцев С.С.

Журнал: Вестник гематологии @bulletin-of-hematology

Статья в выпуске: 4 т.17, 2021 года.

Бесплатный доступ

В библиотеках Pubmed и Medline выполнен поиск литературных источников, в которых были затронуты проблемы заготовки аутотрансплантата у больных множественной миеломой (ММ), а также проанализирован собственный опыт применения режима мобилизации (РМ) с разной интенсивностью цитостатической составляющей. Изучены данные 79 публикаций, посвященные данной теме. Анализ литературных данных свидетельствуют о выраженной мобилизационной активности режима мобилизации (РМ) с включением высокодозного циклофосфана (ЦФ). Менее токсичная схема, цитостатическая составляющая которой представлена винорелбином, привлекательна по причине возможности спрогнозировать в большинстве случаев сроки инициации первого сеанса лейкоцитафереза и низкой частоты осложнений. Результаты собственных исследований в целом соответствуют цифрам других авторов. Признавая клиническую потребность в РМ без введения цитостатиков, проанализированы сообщения других авторов о мобилизационном потенциале комбинации Г-КСФ с плериксафором. Сообщается о короткой продолжительности схемы (не более 5 дней), низкой частоте случаев с повторным введением плериксафора и редких эпизодах токсических осложнений. Таким образом актуальность проблемы эффективности РМ без назначения цитостатических препаратов является несомненно актуальной.

Еще

Множественная миелома, мобилизация стволовых клеток, аутологичная трансплантация гемопоэтических стволовых клеток.

Короткий адрес: https://sciup.org/170179244

IDR: 170179244

Список литературы Мобилизация гемопоэтических стволовых клеток из костного мозга в периферическую кровь у больных множественной миеломой

Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell’Adulto Multiple Myeloma Working Party study / P. Musto, V. Simeon, A. Grossi et al. // Stem. Cell. Res. Ther. – 2015. – Vol. 6. – P. 64.
Proposed definition of “poor mobilizer” in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo / A. Olivieri, M. Marchetti, R. Lemoli et al. // Bone. Marrow. Transplant. – 2012. – Vol. 47. – P. 342–351.
To L.B., Levesque J.P., Herbert K.E. How I treat patients who mobilize hematopoietic stem cells poorly // Blood. – 2011. – Vol. 118. – P. 4530–4540.
Gertz MA. Current status of stem cell mobilization // Br. J. Haematol. – 2010. – Vol. 150. – P. 647–662.
Impairment of filgrastim induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma / U. Popat, R. Saliba, R. Thandi et al. // Biol. Blood. Marrow. Transplant. – 2009. – Vol. 15. – P. 718–723.
Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients (letter) / A. Mazumder, J. Kaufman, R. Niesvizky et al. // Leukemia. – 2008. – Vol. 22. – P. 1280–1281.
Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations / S. Giralt, L. Costa, J. Schriber et al. // Biol. Blood. Marrow. Transplant. – 2014. – Vol. 20. – P. 295–308.
Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation / H.K. Duong, B.N. Savani, E. Copelan et al. // Biol. Blood. Marrow. Transplant. – 2014. – Vol. 20. – P. 1262–1273.
Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone / A.D. Sung, D.T. Grima, L.M. Bernard et al. // Bone. Marrow. Transplant. – 2013. – Vol. 48. – P. 1444–1449.
Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma / M.A. Gertz, S.K. Kumar, M.Q. Lacy et al. // Bone. Marrow. Transplant. – 2009. – Vol. 43. – P. 619–625.
Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma / M. Arora, L.J. Burns, J.N. Barker et al. // Biol. Blood. Marrow. Transplant. – 2004. – Vol. 10. – P. 395–404.
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma / T. Mark, J. Stern, J.R. Furst et al. // Biol. Blood. Marrow. Transplant. – 2008. – Vol. 14. – P. 795–798.
Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization / L.J. Costa, A.N. Miller, E.T. Alexander et al. // Bone. Marrow. Transplant. – 2011. – Vol. 46. – P. 523–528.
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma / J. DiPersio, E.A. Stadtmauer, A. Nademanee et al. // Blood. – 2009. – Vol. 113. – P. 5720–5726.
Плериксафор у пациентов со сниженной мобилизационной способностью аутологичных гемопоэтических стволовых клеток / М.А. Кучер, М.С. Моталкина, О.Ю. Климова и др. // Клиническая онкогематология. – 2016. – №. 2. – С. 155–161.
Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor / J.P. Levesque, Y. Takamatsu, S.K. Nilsson et al. // Blood. – 2001. – Vol. 98. – P. 1289–1297.
Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide / J.P. Levesque, J. Hendy, Y. Takamatsu et al. // J. Clin. Invest. – 2003. – Vol. 111. – P. 187–196.
G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and upregulating CXCR4 / I. Petit, M. Szyper-Kravitz, A. Nagler et al. // Nat. Immunol. – 2002. – Vol. 3. – P. 687–694.
CD34+ cells mobilized by cyclophosphamide and granulocyte colony stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF / C. Cesana, C. Carlo-Stella, E. Regazzi et al. // Bone. Marrow. Transplant. – 1998. – Vol. 21. – P. 561–568.
Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor / I. Bruns, U. Steidl, J.C. Fischer et al. // Haematologica. – 2008. – Vol. 93. – P. 347–355.
Kim MG, Han N, Lee EK, Kim T. Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis // Bone. Marrow. Transplant. – 2015. – Vol. 50. – P. 523–530.
Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma / S.A. Tuchman, W.A. Bacon, L.W. Huang et al. // J. Clin. Apher. – 2015. – Vol. 30. – P. 176–182.
Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma / D. Dingli, G.S. Nowakowski, A. Dispenzieri et al. // Clin. Lymphoma. Myeloma. – 2006. – Vol. 6. – P. 384–388.
Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies / M. Hamadani, S.T. Kochuparambil, S. Osman et al. // Biol. Blood. Marrow. Transplant. – 2012. – Vol. 18. – P. 1128–1135.
Hiwase DK, Bollard G, Hiwase S. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma // Cytotherapy. – 2007. – Vol. 9. – P. 539–547.
Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony stimulating factor for progenitor cell mobilisation in patients with multiple myeloma / E. Jantunen, M. Putkonen, T. Nousiainen et al. // Bone. Marrow. Transplant. – 2003. – Vol. 31. – P. 347–351.
Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen / A. Nazha, R. Cook, D.T. Vogl et al. // Bone. Marrow. Transplant. – 2011. – Vol. 46. – P. 59–63.
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation / A. Brioli, G. Perrone, F. Patriarca et al. // Bone. Marrow. Transplant. – 2015. – Vol. 50. – P. 673–678.
Efficacy of vinorelbine plus granulocyte colony stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma / P. Samaras, S. Pfrommer, B. Seifert et al. // Biol. Blood. Marrow. Transplant. – 2015. – Vol. 21. – P. 74–80.
Efficient mobilization of PBSC with vinorelbine/G-CSF in patients with malignant lymphoma / M. Heizmann, A.C. O’Meara, P.R. Moosmann et al. // Bone. Marrow. Transplant. – 2009. – Vol. 44. – P. 75–79.
Vinorelbine plus intermediate dose cyclophosphamide is an effective and safe regimen for the mobilization of peripheral blood stem cells in patients with multiple myeloma / M. Annunziata, M. Celentano, B. Pocali et al. // Ann Hematol. – 2006. – Vol. 85. – P. 394–399.
Mobilization of peripheral blood progenitor cells with vinorelbine and granulocyte colony-stimulating factor in multiple myeloma patients is reliable and cost effective / M.J. Bargetzi, J. Passweg, E. Baertschi et al. // Bone. Marrow. Transplant. – 2003. – Vol. 31. – P. 99–103.
Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial) / A. Schmid, D. Friess, B.M. Taleghani et al. // Leuk. Lymphoma. – 2015. – Vol. 56. – P. 608–614.
Грицаев С.В., Кузяева А.А., Бессмельцев С.С. Отдельные аспекты трансплантации аутологичных гемопоэтических стволовых клеток больным множественной миеломой // Клиническая онкогематология. – 2017. – № 1. – С.7–12.
Gertz M.A. Current status of stem cell mobilization // Br. J. Haematol. – 2010. – Vol. 150. – P. 647–662.
Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations / S. Giralt, L. Costa, J. Schriber et al. // Biol. Blood. Marrow. Transplant. – 2014. – Vol. 20. – P. 295–308.
Mobilisation of tumour cells along with CD34+ cells to peripheral blood in multiple myeloma / L.M. Knudsen, T. Rasmussen, K. Nikolaisen et al // Eur. J. Haematol. – 2001. – Vol. 67. – P.289–295.
Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation / U. Narayanasami, R. Kanteti, J. Morelli et al. // Blood. – 2001. – Vol. 98. – P. 2059–2064.
Effectiveness of an algorithm-based approach to the utilization of plerixafor in patients undergoing chemotherapy-based stem cell mobilization / E. Chow, K.V. Rao, W.A. Wood et al // Biol. Blood. Marrow. Transplant. – 2014. – Vol. 20. – P. 1064–1068.
Quantification of peripheral blood CD34+ cells prior to stem cell harvesting by leukapheresis: a single center experience / N.E. Lemosa, M.G. Farias, F. Kubaski et al. // Hematol. Transfus. Cell. Ther. – 2018. – Vol. 40. – P. 213–218.
Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma / T.L. Lin, P.N. Wang, M.C. Kuo et al. // J. Clin. Apher. – 2016. – Vol. 31. – P. 423–428.
Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo Italiano Trapianto di Midollo Osseo / A. Olivieri, M. Marchetti, R. Lemoli et al. // Bone. Marrow. Transplant. – 2012. – Vol. 47. – P. 342–351.
Mobilization and collection of peripheral blood stem cells: guidelines for blood volume to process, based on CD34-positive blood cell count in adults and children / A.T. Anguita-Compagnon, M.T. Dibarrart, J. Palma et al. // Transplantat. Proc. – 2010. – Vol. 42. – P. 339–344.
Target value tailored (TVT) apheresis approach for blood progenitor cell collection after high-dose chemotherapy and rh-G-CSF / M.Mitterer, J. Hirber, I. Gentilini et al. // Bone. Marrow. Transplant. – 1996. – Vol. 18. – P. 611–617.
Improved prediction of CD34+ cell yield before peripheral blood hematopoietic progenitor cell collection using a modified target value-tailored approach / D. Sheppard, J. Tay, D. Palmer et al. // Biol. Blood. Marrow. Transplant. – 2016. – Vol. 22. – P. 759–775.
Large-volume leukapheresis yields more viable CD34 + cells and colony-forming units than normal-volume leukapheresis, especially in patients who mobilize low numbers of CD34 + cells / J.F. Abrahamsen, S. Stamnesfet, K. Liseth et al. // Transfusion. – 2005. – Vol. 45. – P. 248–253.
Collection of more hematopoietic progenitor cells with large volume leukapheresis in patients with multiple myeloma / K.R. Desikan, S. Jagannath, D. Siegel et al. // Leuk. Lymphoma. – 1998. – Vol. 28. – P. 501–508.
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie Ematologiche dell’Adulto Multiple Myeloma Working Party study / P. Musto, V. Simeon, A. Grossi et al. // Stem. Cell. Res. Ther. – 2015. – Vol. 6. – P. 64.
Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma / M.A. Gertz, R.C. Wolf, I.N. Micallef et al. // Bone. Marrow. Transplant. – 2010. – Vol. 45. – P. 1396–1403.
Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs / G. Milone, M. Martino, A. Spadaro et al. // Br. J. Haematol. – 2014. – Vol. 164. – P. 113–123.
Analysis of CD34+ cell collection using two mobilization regimens for newly diagnosed multiple myeloma patients reveals the separate impact of mobilization and collection variables / A. Abuabdou, E.R. Rosenbaum, S.Z. Usmani et al. // J. Clin. Apher. – 2014. – Vol. 29. – P. 251–255.
Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF / T. Demirer, M. Ayli, M. Ozcan et al. // Br. J. Haematol. – 2002. – Vol. 116. – P. 468–474.
The effect of gradual increment in rhG-CSF dose on stem cell yields in patients with multiple myeloma mobilized with intermediate dose cyclophosphamide plus rhG-CSF / S. Hacıoglu, I. Sar, M.H. Dogu et al. // Transfus. Apher. Sci. – 2014. – Vol. 50. – P. 71–74.
Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma / S.A. Tuchman, W.A. Bacon, L.W. Huang et al. // J. Clin. Apher. – 2015. – Vol. 30. – P. 176–182.
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma / T. Mark, J. Stern, J.R. Furst et al. // Biol. Blood. Marrow. Transplant. – 2008. – Vol. 14. – P. 795–798.
Заготовка гемопоэтических стволовых клеток у больных множественной миеломой: влияние леналидомида в индукционной терапии и режима мобилизации / И.И. Кострома, А.А. Жернякова, Ж.В. Чубукина и др. // Клиническая онкогематология. – 2018. – №2. – С. 192–197.
Факторы, ассоциированные с эффективной заготовкой и приживлением аутотрансплантата у больных множественной миеломой / И.И. Кострома, А.А. Жернякова, Ж.В. Чубукина и др. // Клиническая онкогематология. – 2019. – №1. – С. 32–36.
Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma / D. Bhutani., J. Zonder, J. Valent et al. // Support. Care. Cancer. – 2013. – Vol. 21. – P. 2437–2442.
Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin’s lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients / S. Fruehauf, G. Ehninger, K. Hubel et al. // Bone. Marrow. Transplant. – 2010. – Vol. 45. – P. 269–275.
Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma / G.H. Ozsan, I.N. Micallef, A. Dispenzieri et al. // Am. J. Hematol. – 2012. – Vol. 87. – P. 1–4.
Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective trial PREDICT / N. Russell, K. Douglas, A.D. Ho et al. // Haematologica. – 2013. – Vol. 98. – P. 172–178.
Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma / D.A. Stewart, C. Smith, R. MacFarland et al. // Biol. Blood. Marrow. Transplant. – 2009. – Vol. 15. – P. 39–46.
Late afternoon dosing of plerixafor for stem cell mobilization: a practical solution / D.L. Cooper, K. Pratt, J. Baker et al. // Clin. Lymphoma. Myeloma. – 2011. – Vol. 11. – P. 267–272.
Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma / R.D. Harvey, J.L. Kaufman, H.R. Johnson et al. // Biol. Blood. Marrow. Transplant. – 2013. – Vol. 19. – P. 1393–1411.
Shi P.A., Miller L.K., Isola L.M. Prospective study of mobilization kinetics up to 18 hours after late afternoon dosing of plerixafor // Transfusion. – 2014. – Vol. 54. – P. 1263–1268.
Evaluation of hematopoietic stem Cell mobilization rates with early plerixafor administration for adult stem cell transplantation / J. Stover, J.R. Shaw, M. Kuchibhatla et al. // Biol. Blood. Marrow. Transplant. – 2017. – Vol. 23. – P. 1290–1294.
Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies / F. Awan, S.T. Kochuparambil, A. Falconer et al. // Bone. Marrow. Transplant. – 2013. – Vol. 48. – P. 1279–1284.
Growth factor plus preemptive (‘just-in-time’) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure / L.J. Costa, J. Abbas, K.R. Hogan et al. // Bone. Marrow. Transplant. – 2012. – Vol. 47. – P. 1403–1408.
Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide / I.N. Micallef, A.D. Ho, L.M. Klein et al. // Bone. Marrow. Transplant. – 2011. – Vol. 46. – P. 350–355.
Optimization of plerixafor utilization based on peripheral blood CD34+ count for autologous peripheral blood stem-cell collection / G.K. Gupta, S. Perreault, S. Seropian et al. / Blood. – 2020. – Vol. 136. – Suppl. 1. – P. 41.
Incorporating reduced-dose plerixafor to a preemptive mobilization algorithm increases access to autologous transplantation in a limited-resource setting / A.G. de Leon, Navarro, C.O. Cantu et al. // Blood. – 2019. – Vol. 134. – Suppl. 1. – P. 4476.
A retrospective record review of mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma / T.M. Mark, J.S. Bubalo, G. Milkovich et al. // Blood. – 2019. – Vol. 134. – Suppl. 1. – P. 5634.
Are We choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely? A single center comparison of GCSF+/-plerixafor vs cyclophosphamide/GCSF+/- plerixafor / Yang, M. Dehghani, W. Hopman et al. // Blood. – 2019. – Vol. 134. – Suppl. 1. – P. 2136.
Заготовка трансплантата для аутологичной трансплантации гемопоэтических стволовых клеток онкогематологическим больным: частота и причины // С.В. Грицаев, А.А. Кузяева, С.В. Волошин и др. // Российский медицинский журнал. – 2013. – №. 1. – С. 30-35.
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial / P.M. Voorhees, J.L. Kaufman, J. Laubach et al. // Blood. – 2020. – Vol. 136. – P. 936–945.
Impact of daratumumab on stem cell collection, graft composition and engraftment among multiple myeloma patients undergoing autologous stem cell transplant / S. Manjappa, R. Fox, J. Reese et al. // Blood. – 2020. – Vol. 136. – Suppl. 1. – P. 35–37.
Первый опыт мобилизации гемопоэтических стволовых клеток в периферическую кровь винорелбином у больных лимфопролиферативными заболеваниями / С.В. Грицаев, А.А. Кузяева, И.И. Кострома и др. // Medline.ru. – 2017. – Том. 18. – С. 409-424.
Колониеобразующая способность гемопоэтических стволовых клеток и количество CD34+ клеток в продукте лейкоцитафереза при различных режимах мобилизации у больных множественной миеломой / В.А. Балашова, Ж.В. Чубукина, И.И. Кострома и др.

Еще

Статья научная